FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.
What happened
FDA reviewed Nuvo Life Health's website in August 2025 and found it offered compounded drug products including semaglutide and tirzepatide. The site claimed 'Semaglutide Injection (similar to Ozempic and Wegovy)' and 'Tirzepatide (similar to Mounjaro).' FDA said these claims are false or misleading because compounded drugs are not FDA-approved and the claims imply they are the same as approved products.
What FDA found
The website claimed compounded semaglutide was 'similar to Ozempic and Wegovy' and compounded tirzepatide was 'similar to Mounjaro,' which FDA says falsely implies the compounded products are the same as FDA-approved drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The company introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]The company received misbranded drugs in interstate commerce and delivered or offered them for delivery.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Nuvo Life Health to take immediate action, including ceasing and desisting from using the cited misleading language, and to respond in writing within 15 working days describing steps taken and how it will prevent recurrence.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and their marketing teams
- brands that compare compounded products to FDA-approved drugs
This is a summary. Read the original letter on fda.gov.